Study Purpose:
This is a Phase 1b, multicenter, randomized, placebo-controlled, double-blind study of 28 days, followed by an 18-month open-label extension, designed to evaluate the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of DNL343 in participants with amyotrophic lateral sclerosis (ALS)Study Status:
Not recruiting
Disease:
Amyotrophic Lateral Sclerosis
Study Type:
Interventional
Type of Intervention:
Drug
Intervention Name:
DNL343, Placebo
Placebo:
Yes
Phase:
Phase 1
Study Chair(s)/Principal Investigator(s):
Linus Sun, MD, PhD, Denali Therapeutics Inc.
Clinicaltrials.gov ID:
Neals Affiliated?
No
Coordinating Center Contact Information
Centre for Human Drug Research (CHDR)
Leiden, South Holland, Netherlands
Full Study Summary:
Study Sponsor:
Denali Therapeutics Inc.
Estimated Enrollment:
30
Estimated Study Start Date:
08 / 11 / 2021
Estimated Study Completion Date:
12 / 01 / 2023
Posting Last Modified Date:
01 / 17 / 2023
Date Study Added to neals.org:
08 / 16 / 2021
Minimum Age:
18 Years
Maximum Age:
80 Years
Can participants use Riluzole?
Yes
Key Inclusion Criteria:- Diagnosis of sporadic or familial ALS
- ≤ 4 years since ALS symptom onset
- Stable doses of approved ALS treatments (riluzole and/or edaravone) for at least 2 months prior to screening
- Participants must be able to swallow the study intervention
- Vital capacity >50% predicted at screening
- Women must have been surgically sterilized, be postmenopausal, or for participants of childbearing potential, must not be pregnant, and both the participant and the male partner must use highly effective contraception
- Men, and sex partner if a woman of childbearing potential, must use highly effective contraception
Key Exclusion Criteria:
- Any history of unstable or poorly controlled psychiatric, endocrine, pulmonary, cardiovascular, gastrointestinal, hepatic, pancreatic, renal, metabolic, hematologic, immunologic, or allergic disease, or other major disorders
- Positive serum pregnancy test or currently lactating or breastfeeding
- History of malignancy within 5 years
- History of clinically significant neurologic disorders other than ALS
HonorHealth
Scottsdale, Arizona
85251
United States
University of California at San Diego
San Diego, California
92093
United States
California Pacific Medical Center
San Francisco, California
94115
United States
PPD Orlando
Orlando, Florida
32806
United States
Emory University
Atlanta, Georgia
30322
United States
Atrium Health Neurosciences Institute
Charlotte, North Carolina
28207
United States
Centre for Human Drug Research (CHDR)
Leiden, South Holland
2333
Netherlands